Xofigo and Urinary retention - a phase IV clinical study of FDA data

Summary:

Urinary retention is reported as a side effect among people who take Xofigo (radium ra-223 dichloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Eligard, and have Prostate cancer.

The phase IV clinical study analyzes which people have Urinary retention when taking Xofigo. It is created by eHealthMe based on reports of 4,945 people who have side effects when taking Xofigo from the FDA, and is updated regularly.

What is Xofigo?

Xofigo has active ingredients of radium ra-223 dichloride. eHealthMe is studying from 4,948 Xofigo users. Check the latest studies of Xofigo.

What is Urinary retention?

Urinary retention (the inability to completely or partially empty the bladder) is found to be associated with 1,568 drugs and 1,741 conditions by eHealthMe. Check the latest studies of Urinary retention.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

4,945 people reported to have side effects when taking Xofigo.
Among them, 24 people (0.49%) have Urinary retention.

Among these 24 people:

How long have people been on Xofigo when they have Urinary retention? *

What is the gender of people who have Urinary retention when taking Xofigo? *

female: 0.0 %
male: 100 %

What is the age of people who have Urinary retention when taking Xofigo? *

What are other drugs people take besides Xofigo? *

What are other side effects people have besides Urinary retention? *

Anaemia (lack of blood): 11 people, 45.83%
Haematuria (presence of blood in urine): 8 people, 33.33%
Prostate Cancer: 7 people, 29.17%
General Physical Health Deterioration (weak health status): 6 people, 25.00%
Prostatic Specific Antigen Increased: 6 people, 25.00%
Thrombocytopenia (decrease of platelets in blood): 4 people, 16.67%
Tumor Invasion: 3 people, 12.50%
Unilateral Hydronephrosis (kidney stone that causes obstruction of the ureter): 2 people, 8.33%
Urine Output - Decreased: 2 people, 8.33%
Fever: 2 people, 8.33%

What are the existing conditions these people have? *

Prostate Cancer: 10 people, 41.67%
Metastases To Bone (cancer spreads to bone): 5 people, 20.83%
Prostate Cancer Metastatic: 2 people, 8.33%
Spinal Pain (pain in spine): 1 person, 4.17%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Xofigo and have Urinary retention?

- Check whether Urinary retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xofigo:

Xofigo (4,948 reports)

Browse all side effects of Xofigo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urinary retention:

Urinary retention (1,568 drugs)

Browse all the conditions that are associated with Urinary retention:

Urinary retention (1,741 conditions)

Related publications that referenced our studies

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on radium ra-223 dichloride (the active ingredients of Xofigo) and Xofigo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.